Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Downregulation of MS4A3 promotes TKI resistance in CML

Michael Deininger • 12 Dec 2021
ASH 2021
Chronic Myeloid Leukemia Leukemia

Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, discusses the role of membrane spanning 4-domains A3 (MS4A3), a trans-membrane protein, in tyrosine kinase inhibitor (TKI) resistance. Resistance to TKIs is associated with low MS4A3 expression in patients with chronic myeloid leukemia (CML), as MS4A3 promotes endocytosis of cytokine receptors. Downregulation of MS4A3 additionally shifts CML cells to an immature state, which enables resistance to TKIs. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Michael Deininger

1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
1:09
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
Michael Deininger • 21 Oct 2022
1:33
ESH CML workshop highlights: 3D genomics and nuclear organization
Michael Deininger • 21 Oct 2022
1:10
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
Michael Deininger • 21 Oct 2022

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals